Compare Meta Platforms Inc (META) vs Novavax Inc (NVAX) Price & Performance

META stock trades at $721.31, down 2.38% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish trend per moving averages, with key support at $719 and resistance at $726. Recent financials reveal strong revenue growth to $201.0B in 2025 and a net income margin of 29.84%, though Q2 2026 EPS missed expectations. The launch of the Muse Spark AI model and a $21B deal with CoreWeave highlight strategic initiatives driving investor optimism, countered by ongoing legal challenges over youth addiction.

The outlook for META remains positive with an 80% analyst buy rating and a consensus price target of $781, suggesting ~8% upside. Key opportunities include AI monetization and robust cash flow growth, while risks involve regulatory lawsuits and high capital expenditures. Investors should weigh strong profitability against legal and competitive pressures in the social media sector.

Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.

The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.